Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network
- PMID: 8622656
- PMCID: PMC231094
- DOI: 10.1128/MCB.16.3.1115
Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network
Abstract
Hepatocyte growth factor/scatter factor (HGF/SF) is a pleiotropic effector of cells expressing the Met tyrosine kinase receptor. Although HGF/SF is synthesized by mesenchymal cells and acts predominantly on epithelial cells, we have recently demonstrated that human sarcoma cell lines often inappropriately express high levels of Met and respond mitogenically to HGF/SF. In the present report we show that HGF/SF-Met signalling in the human leiomyosarcoma cell line SK-LMS-1 enhances its in vivo tumorigenicity, an effect for which the mitogenicity of this signalling pathway is likely to play a role. In addition, we found that HGF/SF-Met signalling dramatically induces the in vitro invasiveness and in vivo metastatic potential of these cells. We have studied the molecular basis by which HGFSF-Met signalling mediates the invasive phenotype. A strong correlation has previously been demonstrated between the activation of the urokinase plasminogen activator (uPA) proteolysis network and the acquisition of the invasive-metastatic phenotype, and we show here that HGF/SF-Met signalling significantly increases the protein levels of both uPA and its cellular receptor in SK-LMS-1 cells. This results in elevated levels of cell-associated uPA and enhanced plasmin-generating ability by these cells. These studies couple HGF/SF-Met signalling to the activation of proteases that mediate dissolution of the extracellular matrix-basement membrane, and important property for cellular invasion-metastasis.
Similar articles
-
The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.Cancer Res. 2000 Jan 15;60(2):342-9. Cancer Res. 2000. PMID: 10667586
-
Met-HGF/SF: tumorigenesis, invasion and metastasis.Ciba Found Symp. 1997;212:119-30; discussion 130-2, 148-54. doi: 10.1002/9780470515457.ch8. Ciba Found Symp. 1997. PMID: 9524767 Review.
-
Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma.Mol Cancer Ther. 2009 Oct;8(10):2803-10. doi: 10.1158/1535-7163.MCT-09-0125. Mol Cancer Ther. 2009. PMID: 19825800
-
Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion.Oncogene. 2005 May 26;24(23):3697-707. doi: 10.1038/sj.onc.1208499. Oncogene. 2005. PMID: 15782129
-
Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis.J Mol Med (Berl). 1996 Sep;74(9):505-13. doi: 10.1007/BF00204976. J Mol Med (Berl). 1996. PMID: 8892055 Review.
Cited by
-
Fibroblasts--a key host cell type in tumor initiation, progression, and metastasis.Ups J Med Sci. 2012 May;117(2):187-95. doi: 10.3109/03009734.2012.654859. Epub 2012 Apr 17. Ups J Med Sci. 2012. PMID: 22509805 Free PMC article.
-
Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line.Br J Cancer. 1999 Aug;80(11):1708-17. doi: 10.1038/sj.bjc.6690587. Br J Cancer. 1999. PMID: 10468286 Free PMC article.
-
Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells.Jpn J Cancer Res. 1999 Jul;90(7):747-52. doi: 10.1111/j.1349-7006.1999.tb00810.x. Jpn J Cancer Res. 1999. PMID: 10470287 Free PMC article.
-
Met-HGF/SF signal transduction induces mimp, a novel mitochondrial carrier homologue, which leads to mitochondrial depolarization.Neoplasia. 2002 Nov-Dec;4(6):510-22. doi: 10.1038/sj.neo.7900272. Neoplasia. 2002. PMID: 12407445 Free PMC article.
-
Special issue: "MET as actionable target in cancer therapy".Ann Transl Med. 2017 Jan;5(1):1. doi: 10.21037/atm.2017.01.10. Ann Transl Med. 2017. PMID: 28164086 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous